BioPharmSignal logoBioPharmSignal

Biotech News

MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment

MediciNova (MNOV)MediciNovaCompany update

LA JOLLA, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the U.S.

Related news

MNOVMediciNova2026-07-15 12:00 EST

MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients

MNOVMediciNova2026-06-30 12:00 EST

MediciNova CEO Provides Shareholder Update

XERSXeris Pharmaceuticals2026-06-11 20:39 EST

Xeris Biopharma Announces Notice of Allowance From U.S. Patent and Trademark Office for New Patent Covering KEVEYIS®

PRAXPraxis Precision Medicines2026-06-22 12:00 EST

Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of Function Variants

AXSMAxsome2026-07-15 11:00 EST

Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy

IKTInhibikase Therapeutics2026-07-23 12:00 EST

Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH

PRAXPraxis Precision Medicines2026-06-29 20:30 EST

Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies

BTAIBioXcel2026-05-28 11:00 EST

BioXcel Therapeutics Presents New Data from SERENITY At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia at 2026 ASCP Annual Meeting

TSHATaysha Gene Therapies2026-08-03 12:00 EST

Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome

ANNXAnnexon, Inc.2026-07-30 20:01 EST

Annexon Secures Strategic Credit Facility for up to $200 Million from Oxford Finance

View all latest news

MediciNova

MediciNova is a biotechnology company with programs in inflammation, fibrosis, and neurological disease. Its story is built around repurposing and selective development rather than broad commercial scale.

Recent company news

MNOVMediciNova2026-07-15 12:00 EST

MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients

MNOVMediciNova2026-06-30 12:00 EST

MediciNova CEO Provides Shareholder Update

MNOVMediciNova2026-06-08 12:00 EST

MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment

MNOVMediciNova2026-05-26 23:00 EST

MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)

MNOVMediciNova2026-04-27 23:00 EST

New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation

Stock data

Close
1.36 USD
Market cap
65.96M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States